Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/b04dea95-0a16-435d-87ff-4abf7281c5e6/

CSCI

COSCIENS Biopharma Inc.
Chart
2.56 CAD
Latest Week 2026-06-05
HealthcareBiotechnologyNANO
Snapshot 2026-06-07 · 0.0w · Fresh
0.6
OS Score
54.0%
Value
54.0%
Quality
56.0%
Momentum
2/9
F-Score
0.540
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
54.0%ile
P/E
2.0×
P/S
1.0×
P/B
0.5×
FCF Yield
-1.715
SH Yield
0.005
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
47.00000000
/100 — 1=cheapest
VC2 (Trending Value)
46.00000000
/100
VC3 (Buyback)
46.00000000
/100
P/E of 2.0x places this firmly in deep value territory. Negative FCF yield (-171.5%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
54.0%ile
ROE
0.265
ROA
0.215
Net Margin
0.514
Op Margin
-0.948
GPA
0.159
Current
5.57
F-Score
2/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
-0.218
Stability
75.295
lower=better
Accruals
0.681
lower=better
5yr Consist
No
ROE of 26% is exceptional. Accruals ratio of 0.681 is elevated — earnings quality may be lower than headline numbers suggest. F-Score of 2/9 flags fundamental deterioration — multiple signals are weakening.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
56.0%ile
6M Return
-11.7%
12M Return
-48.1%
12-1 Mom
-47.5%
Risk-Adj
-0.41
Vol 252d
116.2%
Vol 60d
278.8%
↑ Expanding
Max DD 12M
-80.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -47% signals a downtrend — price is moving against you. Near-term vol (279%) is expanding vs long-term (116%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.6
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 45 peers
Sector Value %ile
56.5%
Sector Quality %ile
63.0%
P/E z-score
-1.13
P/B z-score
-0.72
Sector Avg OS
46.8%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
XLY Auxly Cannabis Group Inc. 98.0% 96.0% 86.0% 85.0%
LOVE Cannara Biotech Inc. 95.0% 92.0% 82.0% 69.0%
DR Medical Facilities Corporation 91.0% 90.0% 91.0% 29.0%
BHC Bausch Health Companies Inc. 90.0% 87.0% 96.0% 27.0%
TSND TerrAscend Corp. 86.0% 63.0% 62.0% 93.0%
MDP Medexus Pharmaceuticals Inc. 83.0% 62.0% 77.0% 67.0%
CRRX CareRx Corporation 81.0% 81.0% 68.0% 29.0%
TLRY Tilray Brands, Inc. 80.0% 75.0% 6.0% 99.0%
Factor Interactions
Earnings Quality Concern
ROE looks strong (26%) but high accruals (0.681) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (279%) significantly exceeds 252-day (116%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
62.3% avg (5 factors)
Quality
C
58.2% avg (7 factors)
Momentum
F
9.4% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.600—0—
Value %ile0.540—0—
Quality %ile0.540—0—
Momentum %ile0.560—0—
F-Score2.000—1—
Confidence0.818—1—
Volatility1.162—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
2.01
Price / Sales
1.03
Price / Book
0.53
FCF Yield
-171.5%
Sales Yield (1/P·S)
1.5255
Shareholder Yield
Div + net buyback / mktcap
0.5%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
26.5%
Return on Assets
21.5%
Net Margin
51.4%
Operating Margin
-94.8%
Gross Profit / Assets
Novy-Marx GPA
15.9%
Current Ratio
5.57
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.681
MomentumPrice trend strength over different horizons
6M Return
-11.7%
12M Return
-48.1%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-47.5%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.41
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
-21.8%
Earnings Stability (CV)
Lower = more stable
75.295
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
2
Dividend Yield
0.0%
Buyback Yield
0.5%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
47
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
46
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
46
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity